Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.
Sandro HolzerNeil J RzechorzekIsobel R ShortMichael Jenkyn-BedfordLuca PellegriniMairi L KilkennyPublished in: ACS chemical biology (2019)
Nucleoside analogues are widely used in clinical practice as chemotherapy drugs. Arabinose nucleoside derivatives such as fludarabine are effective in the treatment of patients with acute and chronic leukemias and non-Hodgkin's lymphomas. Although nucleoside analogues are generally known to function by inhibiting DNA synthesis in rapidly proliferating cells, the identity of their in vivo targets and mechanism of action are often not known in molecular detail. Here we provide a structural basis for arabinose nucleotide-mediated inhibition of human primase, the DNA-dependent RNA polymerase responsible for initiation of DNA synthesis in DNA replication. Our data suggest ways in which the chemical structure of fludarabine could be modified to improve its specificity and affinity toward primase, possibly leading to less toxic and more effective therapeutic agents.
Keyphrases
- structural basis
- circulating tumor
- single molecule
- endothelial cells
- cell free
- molecular docking
- clinical practice
- structure activity relationship
- induced pluripotent stem cells
- pluripotent stem cells
- nucleic acid
- cell proliferation
- electronic health record
- machine learning
- big data
- oxidative stress
- locally advanced
- cell cycle arrest